nodes	percent_of_prediction	percent_of_DWPC	metapath
Pethidine—ORM1—Vismodegib—skin cancer	0.222	0.264	CbGbCtD
Pethidine—ORM1—Vemurafenib—skin cancer	0.175	0.209	CbGbCtD
Pethidine—ALB—Vismodegib—skin cancer	0.0932	0.111	CbGbCtD
Pethidine—ALB—Vemurafenib—skin cancer	0.0737	0.088	CbGbCtD
Pethidine—CYP2C19—Vismodegib—skin cancer	0.0604	0.0721	CbGbCtD
Pethidine—CYP3A4—Temozolomide—skin cancer	0.0422	0.0503	CbGbCtD
Pethidine—CYP3A4—Imiquimod—skin cancer	0.0422	0.0503	CbGbCtD
Pethidine—CYP2D6—Vemurafenib—skin cancer	0.0363	0.0433	CbGbCtD
Pethidine—ALB—Fluorouracil—skin cancer	0.0331	0.0395	CbGbCtD
Pethidine—CYP3A4—Vismodegib—skin cancer	0.0292	0.0349	CbGbCtD
Pethidine—CYP3A4—Vemurafenib—skin cancer	0.0231	0.0276	CbGbCtD
Pethidine—CYP3A4—Docetaxel—skin cancer	0.00792	0.00946	CbGbCtD
Pethidine—GRIN2C—nerve—skin cancer	0.0055	0.163	CbGeAlD
Pethidine—GRIN2B—nerve—skin cancer	0.00435	0.129	CbGeAlD
Pethidine—Induration—Imiquimod—skin cancer	0.00393	0.04	CcSEcCtD
Pethidine—GRIN2A—nerve—skin cancer	0.0038	0.113	CbGeAlD
Pethidine—Fibrosis—Fluorouracil—skin cancer	0.0034	0.0345	CcSEcCtD
Pethidine—Paralysis—Vemurafenib—skin cancer	0.00297	0.0302	CcSEcCtD
Pethidine—Induration—Bleomycin—skin cancer	0.00279	0.0284	CcSEcCtD
Pethidine—OPRM1—nerve—skin cancer	0.00231	0.0685	CbGeAlD
Pethidine—SLC6A3—nerve—skin cancer	0.0021	0.0621	CbGeAlD
Pethidine—Neurotoxicity—Docetaxel—skin cancer	0.00181	0.0184	CcSEcCtD
Pethidine—SLC6A2—nerve—skin cancer	0.00169	0.0501	CbGeAlD
Pethidine—Muscle spasms—Vismodegib—skin cancer	0.0014	0.0143	CcSEcCtD
Pethidine—GRIN2C—head—skin cancer	0.0013	0.0387	CbGeAlD
Pethidine—Irritability—Imiquimod—skin cancer	0.00122	0.0124	CcSEcCtD
Pethidine—Urinary retention—Imiquimod—skin cancer	0.00121	0.0123	CcSEcCtD
Pethidine—GRIN2D—head—skin cancer	0.00121	0.0359	CbGeAlD
Pethidine—GRIN1—head—skin cancer	0.00108	0.032	CbGeAlD
Pethidine—Coordination abnormal—Temozolomide—skin cancer	0.00107	0.0109	CcSEcCtD
Pethidine—Phlebitis—Bleomycin—skin cancer	0.00105	0.0107	CcSEcCtD
Pethidine—Decreased appetite—Vismodegib—skin cancer	0.00104	0.0105	CcSEcCtD
Pethidine—GRIN2B—head—skin cancer	0.00103	0.0306	CbGeAlD
Pethidine—Constipation—Vismodegib—skin cancer	0.00102	0.0104	CcSEcCtD
Pethidine—Depressed level of consciousness—Temozolomide—skin cancer	0.00102	0.0103	CcSEcCtD
Pethidine—Disorientation—Bleomycin—skin cancer	0.00101	0.0103	CcSEcCtD
Pethidine—Phlebitis—Dactinomycin—skin cancer	0.000982	0.00998	CcSEcCtD
Pethidine—OPRK1—female reproductive system—skin cancer	0.000922	0.0273	CbGeAlD
Pethidine—GRIN2A—head—skin cancer	0.000901	0.0267	CbGeAlD
Pethidine—Erythema—Vemurafenib—skin cancer	0.000901	0.00917	CcSEcCtD
Pethidine—Coma—Fluorouracil—skin cancer	0.000887	0.00902	CcSEcCtD
Pethidine—Asthenia—Vismodegib—skin cancer	0.000854	0.00869	CcSEcCtD
Pethidine—Visual impairment—Imiquimod—skin cancer	0.000851	0.00865	CcSEcCtD
Pethidine—Pruritus—Vismodegib—skin cancer	0.000842	0.00857	CcSEcCtD
Pethidine—Euphoric mood—Fluorouracil—skin cancer	0.000834	0.00848	CcSEcCtD
Pethidine—Flushing—Imiquimod—skin cancer	0.000819	0.00833	CcSEcCtD
Pethidine—Disorientation—Fluorouracil—skin cancer	0.000788	0.00801	CcSEcCtD
Pethidine—OPRK1—head—skin cancer	0.00077	0.0228	CbGeAlD
Pethidine—Erythema—Imiquimod—skin cancer	0.000769	0.00782	CcSEcCtD
Pethidine—Vomiting—Vismodegib—skin cancer	0.000757	0.0077	CcSEcCtD
Pethidine—Affect lability—Temozolomide—skin cancer	0.000753	0.00766	CcSEcCtD
Pethidine—Rash—Vismodegib—skin cancer	0.000751	0.00763	CcSEcCtD
Pethidine—Dermatitis—Vismodegib—skin cancer	0.00075	0.00763	CcSEcCtD
Pethidine—Anaphylactic shock—Vemurafenib—skin cancer	0.000736	0.00748	CcSEcCtD
Pethidine—Mood swings—Temozolomide—skin cancer	0.000725	0.00737	CcSEcCtD
Pethidine—Nausea—Vismodegib—skin cancer	0.000707	0.00719	CcSEcCtD
Pethidine—Agitation—Imiquimod—skin cancer	0.000706	0.00718	CcSEcCtD
Pethidine—Syncope—Imiquimod—skin cancer	0.000689	0.00701	CcSEcCtD
Pethidine—Hypotension—Vemurafenib—skin cancer	0.000687	0.00699	CcSEcCtD
Pethidine—Palpitations—Imiquimod—skin cancer	0.000679	0.00691	CcSEcCtD
Pethidine—Loss of consciousness—Imiquimod—skin cancer	0.000676	0.00687	CcSEcCtD
Pethidine—Irritability—Fluorouracil—skin cancer	0.000673	0.00684	CcSEcCtD
Pethidine—Cardiac arrest—Fluorouracil—skin cancer	0.00067	0.00681	CcSEcCtD
Pethidine—Convulsion—Imiquimod—skin cancer	0.000666	0.00677	CcSEcCtD
Pethidine—Hypertension—Imiquimod—skin cancer	0.000664	0.00675	CcSEcCtD
Pethidine—Anxiety—Imiquimod—skin cancer	0.000652	0.00663	CcSEcCtD
Pethidine—ORM1—female reproductive system—skin cancer	0.00064	0.019	CbGeAlD
Pethidine—Dry mouth—Imiquimod—skin cancer	0.00064	0.00651	CcSEcCtD
Pethidine—Decreased appetite—Vemurafenib—skin cancer	0.000639	0.0065	CcSEcCtD
Pethidine—Constipation—Vemurafenib—skin cancer	0.000629	0.0064	CcSEcCtD
Pethidine—Oedema—Imiquimod—skin cancer	0.000627	0.00638	CcSEcCtD
Pethidine—Lightheadedness—Docetaxel—skin cancer	0.000627	0.00638	CcSEcCtD
Pethidine—Shock—Imiquimod—skin cancer	0.000617	0.00628	CcSEcCtD
Pethidine—Tachycardia—Imiquimod—skin cancer	0.000612	0.00623	CcSEcCtD
Pethidine—Hyperhidrosis—Imiquimod—skin cancer	0.000606	0.00617	CcSEcCtD
Pethidine—Anorexia—Imiquimod—skin cancer	0.000598	0.00608	CcSEcCtD
Pethidine—Phlebitis—Docetaxel—skin cancer	0.00059	0.006	CcSEcCtD
Pethidine—Flushing—Bleomycin—skin cancer	0.000582	0.00592	CcSEcCtD
Pethidine—Insomnia—Imiquimod—skin cancer	0.000567	0.00577	CcSEcCtD
Pethidine—Somnolence—Imiquimod—skin cancer	0.000558	0.00567	CcSEcCtD
Pethidine—OPRM1—head—skin cancer	0.000548	0.0162	CbGeAlD
Pethidine—Erythema—Bleomycin—skin cancer	0.000546	0.00555	CcSEcCtD
Pethidine—SLC6A4—female reproductive system—skin cancer	0.000545	0.0162	CbGeAlD
Pethidine—Decreased appetite—Imiquimod—skin cancer	0.000545	0.00555	CcSEcCtD
Pethidine—Flushing—Dactinomycin—skin cancer	0.000543	0.00552	CcSEcCtD
Pethidine—Hypersensitivity—Vemurafenib—skin cancer	0.000542	0.00551	CcSEcCtD
Pethidine—Visual disturbance—Docetaxel—skin cancer	0.000537	0.00546	CcSEcCtD
Pethidine—Asthenia—Vemurafenib—skin cancer	0.000528	0.00537	CcSEcCtD
Pethidine—Hallucination—Temozolomide—skin cancer	0.000526	0.00535	CcSEcCtD
Pethidine—Pruritus—Vemurafenib—skin cancer	0.00052	0.00529	CcSEcCtD
Pethidine—Feeling abnormal—Imiquimod—skin cancer	0.000517	0.00526	CcSEcCtD
Pethidine—Visual impairment—Temozolomide—skin cancer	0.00051	0.00519	CcSEcCtD
Pethidine—Erythema—Dactinomycin—skin cancer	0.000509	0.00518	CcSEcCtD
Pethidine—Urticaria—Imiquimod—skin cancer	0.000498	0.00507	CcSEcCtD
Pethidine—SLC6A3—head—skin cancer	0.000497	0.0147	CbGeAlD
Pethidine—Flushing—Temozolomide—skin cancer	0.000491	0.00499	CcSEcCtD
Pethidine—Dizziness—Vemurafenib—skin cancer	0.000486	0.00495	CcSEcCtD
Pethidine—SLC6A2—female reproductive system—skin cancer	0.00048	0.0142	CbGeAlD
Pethidine—GRIN2D—Post NMDA receptor activation events—BRAF—skin cancer	0.000479	0.016	CbGpPWpGaD
Pethidine—GRIN2A—CREB phosphorylation through the activation of Ras—BRAF—skin cancer	0.000478	0.0159	CbGpPWpGaD
Pethidine—GRIN2C—Activation of NMDA receptor upon glutamate binding and postsynaptic events—BRAF—skin cancer	0.000475	0.0158	CbGpPWpGaD
Pethidine—Vomiting—Vemurafenib—skin cancer	0.000468	0.00476	CcSEcCtD
Pethidine—Orthostatic hypotension—Docetaxel—skin cancer	0.000465	0.00472	CcSEcCtD
Pethidine—Rash—Vemurafenib—skin cancer	0.000464	0.00472	CcSEcCtD
Pethidine—Dermatitis—Vemurafenib—skin cancer	0.000463	0.00471	CcSEcCtD
Pethidine—GRIN1—Spinal Cord Injury—CSPG4—skin cancer	0.000463	0.0154	CbGpPWpGaD
Pethidine—Hypersensitivity—Imiquimod—skin cancer	0.000462	0.0047	CcSEcCtD
Pethidine—Headache—Vemurafenib—skin cancer	0.000461	0.00469	CcSEcCtD
Pethidine—Erythema—Temozolomide—skin cancer	0.000461	0.00468	CcSEcCtD
Pethidine—OPRK1—Peptide GPCRs—MC1R—skin cancer	0.00046	0.0153	CbGpPWpGaD
Pethidine—SLC6A4—head—skin cancer	0.000456	0.0135	CbGeAlD
Pethidine—CYP2B6—skin of body—skin cancer	0.000453	0.0134	CbGeAlD
Pethidine—Asthenia—Imiquimod—skin cancer	0.00045	0.00458	CcSEcCtD
Pethidine—Confusional state—Bleomycin—skin cancer	0.000449	0.00457	CcSEcCtD
Pethidine—Anaphylactic shock—Bleomycin—skin cancer	0.000446	0.00453	CcSEcCtD
Pethidine—Oedema—Bleomycin—skin cancer	0.000446	0.00453	CcSEcCtD
Pethidine—Pruritus—Imiquimod—skin cancer	0.000444	0.00451	CcSEcCtD
Pethidine—GRIN2D—Activation of NMDA receptor upon glutamate binding and postsynaptic events—BRAF—skin cancer	0.000442	0.0147	CbGpPWpGaD
Pethidine—Nausea—Vemurafenib—skin cancer	0.000437	0.00444	CcSEcCtD
Pethidine—Tremor—Temozolomide—skin cancer	0.000432	0.00439	CcSEcCtD
Pethidine—Anorexia—Bleomycin—skin cancer	0.000425	0.00432	CcSEcCtD
Pethidine—Erythema—Fluorouracil—skin cancer	0.000424	0.00432	CcSEcCtD
Pethidine—Agitation—Temozolomide—skin cancer	0.000423	0.0043	CcSEcCtD
Pethidine—GRIN1—CREB phosphorylation through the activation of Ras—BRAF—skin cancer	0.000417	0.0139	CbGpPWpGaD
Pethidine—Hypotension—Bleomycin—skin cancer	0.000416	0.00423	CcSEcCtD
Pethidine—Oedema—Dactinomycin—skin cancer	0.000416	0.00423	CcSEcCtD
Pethidine—Dizziness—Imiquimod—skin cancer	0.000415	0.00422	CcSEcCtD
Pethidine—Vertigo—Temozolomide—skin cancer	0.000414	0.00421	CcSEcCtD
Pethidine—Palpitations—Temozolomide—skin cancer	0.000407	0.00414	CcSEcCtD
Pethidine—GRIN2B—CREB phosphorylation through the activation of Ras—BRAF—skin cancer	0.000407	0.0135	CbGpPWpGaD
Pethidine—GRIN2C—Ras activation uopn Ca2+ infux through NMDA receptor—HRAS—skin cancer	0.000404	0.0135	CbGpPWpGaD
Pethidine—SLC6A2—head—skin cancer	0.000401	0.0119	CbGeAlD
Pethidine—Convulsion—Temozolomide—skin cancer	0.000399	0.00406	CcSEcCtD
Pethidine—Vomiting—Imiquimod—skin cancer	0.000399	0.00406	CcSEcCtD
Pethidine—Hypertension—Temozolomide—skin cancer	0.000398	0.00404	CcSEcCtD
Pethidine—Anorexia—Dactinomycin—skin cancer	0.000396	0.00403	CcSEcCtD
Pethidine—Rash—Imiquimod—skin cancer	0.000396	0.00402	CcSEcCtD
Pethidine—Dermatitis—Imiquimod—skin cancer	0.000395	0.00402	CcSEcCtD
Pethidine—GRIN2A—Post NMDA receptor activation events—BRAF—skin cancer	0.000394	0.0131	CbGpPWpGaD
Pethidine—Headache—Imiquimod—skin cancer	0.000393	0.004	CcSEcCtD
Pethidine—Anxiety—Temozolomide—skin cancer	0.000391	0.00397	CcSEcCtD
Pethidine—ALB—FOXA2 and FOXA3 transcription factor networks—NKX2-1—skin cancer	0.000389	0.0129	CbGpPWpGaD
Pethidine—OPRM1—Peptide GPCRs—MC1R—skin cancer	0.000389	0.0129	CbGpPWpGaD
Pethidine—Decreased appetite—Bleomycin—skin cancer	0.000387	0.00394	CcSEcCtD
Pethidine—Dry mouth—Temozolomide—skin cancer	0.000384	0.0039	CcSEcCtD
Pethidine—Confusional state—Temozolomide—skin cancer	0.000379	0.00385	CcSEcCtD
Pethidine—Oedema—Temozolomide—skin cancer	0.000376	0.00382	CcSEcCtD
Pethidine—Anaphylactic shock—Temozolomide—skin cancer	0.000376	0.00382	CcSEcCtD
Pethidine—GRIN2D—Ras activation uopn Ca2+ infux through NMDA receptor—HRAS—skin cancer	0.000376	0.0125	CbGpPWpGaD
Pethidine—GRIN1—EPH-Ephrin signaling—RASA1—skin cancer	0.000375	0.0125	CbGpPWpGaD
Pethidine—ORM1—lymph node—skin cancer	0.000375	0.0111	CbGeAlD
Pethidine—Nausea—Imiquimod—skin cancer	0.000373	0.00379	CcSEcCtD
Pethidine—Convulsion—Fluorouracil—skin cancer	0.000368	0.00374	CcSEcCtD
Pethidine—Feeling abnormal—Bleomycin—skin cancer	0.000367	0.00373	CcSEcCtD
Pethidine—CYP2B6—lymphoid tissue—skin cancer	0.000367	0.0109	CbGeAlD
Pethidine—GRIN2B—EPH-Ephrin signaling—RASA1—skin cancer	0.000366	0.0122	CbGpPWpGaD
Pethidine—Hyperhidrosis—Temozolomide—skin cancer	0.000363	0.0037	CcSEcCtD
Pethidine—GRIN2A—Activation of NMDA receptor upon glutamate binding and postsynaptic events—BRAF—skin cancer	0.000363	0.0121	CbGpPWpGaD
Pethidine—Decreased appetite—Dactinomycin—skin cancer	0.000361	0.00367	CcSEcCtD
Pethidine—Anorexia—Temozolomide—skin cancer	0.000358	0.00364	CcSEcCtD
Pethidine—Urticaria—Bleomycin—skin cancer	0.000354	0.0036	CcSEcCtD
Pethidine—CYP2B6—female reproductive system—skin cancer	0.000354	0.0105	CbGeAlD
Pethidine—Confusional state—Fluorouracil—skin cancer	0.000349	0.00355	CcSEcCtD
Pethidine—Oedema—Fluorouracil—skin cancer	0.000346	0.00352	CcSEcCtD
Pethidine—Anaphylactic shock—Fluorouracil—skin cancer	0.000346	0.00352	CcSEcCtD
Pethidine—GRIN1—Post NMDA receptor activation events—BRAF—skin cancer	0.000343	0.0114	CbGpPWpGaD
Pethidine—Feeling abnormal—Dactinomycin—skin cancer	0.000343	0.00348	CcSEcCtD
Pethidine—Insomnia—Temozolomide—skin cancer	0.00034	0.00346	CcSEcCtD
Pethidine—Visual impairment—Docetaxel—skin cancer	0.000339	0.00345	CcSEcCtD
Pethidine—Tachycardia—Fluorouracil—skin cancer	0.000338	0.00344	CcSEcCtD
Pethidine—GRIN2B—Post NMDA receptor activation events—BRAF—skin cancer	0.000335	0.0111	CbGpPWpGaD
Pethidine—Somnolence—Temozolomide—skin cancer	0.000334	0.0034	CcSEcCtD
Pethidine—Anorexia—Fluorouracil—skin cancer	0.00033	0.00336	CcSEcCtD
Pethidine—ALB—lymph node—skin cancer	0.000328	0.00973	CbGeAlD
Pethidine—Hypersensitivity—Bleomycin—skin cancer	0.000328	0.00334	CcSEcCtD
Pethidine—Decreased appetite—Temozolomide—skin cancer	0.000327	0.00332	CcSEcCtD
Pethidine—Flushing—Docetaxel—skin cancer	0.000327	0.00332	CcSEcCtD
Pethidine—Hypotension—Fluorouracil—skin cancer	0.000324	0.00329	CcSEcCtD
Pethidine—Constipation—Temozolomide—skin cancer	0.000321	0.00327	CcSEcCtD
Pethidine—Asthenia—Bleomycin—skin cancer	0.00032	0.00325	CcSEcCtD
Pethidine—GRIN1—Activation of NMDA receptor upon glutamate binding and postsynaptic events—BRAF—skin cancer	0.000316	0.0105	CbGpPWpGaD
Pethidine—Pruritus—Bleomycin—skin cancer	0.000315	0.00321	CcSEcCtD
Pethidine—Insomnia—Fluorouracil—skin cancer	0.000313	0.00319	CcSEcCtD
Pethidine—Feeling abnormal—Temozolomide—skin cancer	0.00031	0.00315	CcSEcCtD
Pethidine—GRIN2A—Ras activation uopn Ca2+ infux through NMDA receptor—HRAS—skin cancer	0.000309	0.0103	CbGpPWpGaD
Pethidine—GRIN2B—Activation of NMDA receptor upon glutamate binding and postsynaptic events—BRAF—skin cancer	0.000308	0.0103	CbGpPWpGaD
Pethidine—Somnolence—Fluorouracil—skin cancer	0.000308	0.00313	CcSEcCtD
Pethidine—Erythema—Docetaxel—skin cancer	0.000306	0.00311	CcSEcCtD
Pethidine—Hypersensitivity—Dactinomycin—skin cancer	0.000306	0.00311	CcSEcCtD
Pethidine—Decreased appetite—Fluorouracil—skin cancer	0.000301	0.00306	CcSEcCtD
Pethidine—Urticaria—Temozolomide—skin cancer	0.000299	0.00304	CcSEcCtD
Pethidine—Asthenia—Dactinomycin—skin cancer	0.000298	0.00303	CcSEcCtD
Pethidine—CYP2B6—head—skin cancer	0.000296	0.00876	CbGeAlD
Pethidine—Muscle spasms—Docetaxel—skin cancer	0.000295	0.00299	CcSEcCtD
Pethidine—GRIN2C—CREB phosphorylation through the activation of Ras—HRAS—skin cancer	0.000288	0.00959	CbGpPWpGaD
Pethidine—Feeling abnormal—Fluorouracil—skin cancer	0.000285	0.0029	CcSEcCtD
Pethidine—Vomiting—Bleomycin—skin cancer	0.000283	0.00288	CcSEcCtD
Pethidine—Rash—Bleomycin—skin cancer	0.000281	0.00286	CcSEcCtD
Pethidine—SLC6A2—lymph node—skin cancer	0.000281	0.00833	CbGeAlD
Pethidine—Dermatitis—Bleomycin—skin cancer	0.000281	0.00285	CcSEcCtD
Pethidine—Hypersensitivity—Temozolomide—skin cancer	0.000277	0.00282	CcSEcCtD
Pethidine—Urticaria—Fluorouracil—skin cancer	0.000275	0.0028	CcSEcCtD
Pethidine—Syncope—Docetaxel—skin cancer	0.000275	0.00279	CcSEcCtD
Pethidine—Palpitations—Docetaxel—skin cancer	0.000271	0.00275	CcSEcCtD
Pethidine—Asthenia—Temozolomide—skin cancer	0.00027	0.00274	CcSEcCtD
Pethidine—Loss of consciousness—Docetaxel—skin cancer	0.000269	0.00274	CcSEcCtD
Pethidine—GRIN1—Ras activation uopn Ca2+ infux through NMDA receptor—HRAS—skin cancer	0.000269	0.00896	CbGpPWpGaD
Pethidine—GRIN2D—CREB phosphorylation through the activation of Ras—HRAS—skin cancer	0.000268	0.00892	CbGpPWpGaD
Pethidine—CYP3A4—female reproductive system—skin cancer	0.000267	0.00792	CbGeAlD
Pethidine—SLC6A4—Circadian rythm related genes—NKX2-1—skin cancer	0.000267	0.00889	CbGpPWpGaD
Pethidine—Pruritus—Temozolomide—skin cancer	0.000266	0.0027	CcSEcCtD
Pethidine—Convulsion—Docetaxel—skin cancer	0.000265	0.0027	CcSEcCtD
Pethidine—Nausea—Bleomycin—skin cancer	0.000265	0.00269	CcSEcCtD
Pethidine—Hypertension—Docetaxel—skin cancer	0.000264	0.00269	CcSEcCtD
Pethidine—Vomiting—Dactinomycin—skin cancer	0.000264	0.00269	CcSEcCtD
Pethidine—CYP2D6—female reproductive system—skin cancer	0.000263	0.00779	CbGeAlD
Pethidine—GRIN2B—Ras activation uopn Ca2+ infux through NMDA receptor—HRAS—skin cancer	0.000262	0.00873	CbGpPWpGaD
Pethidine—Rash—Dactinomycin—skin cancer	0.000262	0.00266	CcSEcCtD
Pethidine—Hypersensitivity—Fluorouracil—skin cancer	0.000255	0.0026	CcSEcCtD
Pethidine—Dry mouth—Docetaxel—skin cancer	0.000255	0.00259	CcSEcCtD
Pethidine—Confusional state—Docetaxel—skin cancer	0.000252	0.00256	CcSEcCtD
Pethidine—Anaphylactic shock—Docetaxel—skin cancer	0.00025	0.00254	CcSEcCtD
Pethidine—Oedema—Docetaxel—skin cancer	0.00025	0.00254	CcSEcCtD
Pethidine—Dizziness—Temozolomide—skin cancer	0.000249	0.00253	CcSEcCtD
Pethidine—Nausea—Dactinomycin—skin cancer	0.000247	0.00251	CcSEcCtD
Pethidine—Shock—Docetaxel—skin cancer	0.000246	0.0025	CcSEcCtD
Pethidine—Pruritus—Fluorouracil—skin cancer	0.000245	0.00249	CcSEcCtD
Pethidine—Tachycardia—Docetaxel—skin cancer	0.000244	0.00248	CcSEcCtD
Pethidine—GRIN1—Axon guidance—SCN10A—skin cancer	0.000243	0.00809	CbGpPWpGaD
Pethidine—Vomiting—Temozolomide—skin cancer	0.000239	0.00243	CcSEcCtD
Pethidine—Anorexia—Docetaxel—skin cancer	0.000238	0.00242	CcSEcCtD
Pethidine—GRIN2C—Post NMDA receptor activation events—HRAS—skin cancer	0.000237	0.00789	CbGpPWpGaD
Pethidine—Rash—Temozolomide—skin cancer	0.000237	0.00241	CcSEcCtD
Pethidine—Dermatitis—Temozolomide—skin cancer	0.000237	0.00241	CcSEcCtD
Pethidine—GRIN2B—Axon guidance—SCN10A—skin cancer	0.000237	0.00788	CbGpPWpGaD
Pethidine—Headache—Temozolomide—skin cancer	0.000236	0.00239	CcSEcCtD
Pethidine—Hypotension—Docetaxel—skin cancer	0.000234	0.00238	CcSEcCtD
Pethidine—Dizziness—Fluorouracil—skin cancer	0.000229	0.00233	CcSEcCtD
Pethidine—Insomnia—Docetaxel—skin cancer	0.000226	0.0023	CcSEcCtD
Pethidine—Nausea—Temozolomide—skin cancer	0.000223	0.00227	CcSEcCtD
Pethidine—Somnolence—Docetaxel—skin cancer	0.000222	0.00226	CcSEcCtD
Pethidine—GRIN2D—Post NMDA receptor activation events—HRAS—skin cancer	0.00022	0.00734	CbGpPWpGaD
Pethidine—Vomiting—Fluorouracil—skin cancer	0.00022	0.00224	CcSEcCtD
Pethidine—GRIN2A—CREB phosphorylation through the activation of Ras—HRAS—skin cancer	0.00022	0.00732	CbGpPWpGaD
Pethidine—CYP2D6—head—skin cancer	0.00022	0.00651	CbGeAlD
Pethidine—GRIN2C—Activation of NMDA receptor upon glutamate binding and postsynaptic events—HRAS—skin cancer	0.000218	0.00727	CbGpPWpGaD
Pethidine—Rash—Fluorouracil—skin cancer	0.000218	0.00222	CcSEcCtD
Pethidine—Dermatitis—Fluorouracil—skin cancer	0.000218	0.00222	CcSEcCtD
Pethidine—Decreased appetite—Docetaxel—skin cancer	0.000217	0.00221	CcSEcCtD
Pethidine—Headache—Fluorouracil—skin cancer	0.000217	0.00221	CcSEcCtD
Pethidine—OPRK1—Peptide ligand-binding receptors—MC1R—skin cancer	0.000216	0.0072	CbGpPWpGaD
Pethidine—Constipation—Docetaxel—skin cancer	0.000214	0.00217	CcSEcCtD
Pethidine—Feeling abnormal—Docetaxel—skin cancer	0.000206	0.00209	CcSEcCtD
Pethidine—Nausea—Fluorouracil—skin cancer	0.000206	0.00209	CcSEcCtD
Pethidine—GRIN2D—Activation of NMDA receptor upon glutamate binding and postsynaptic events—HRAS—skin cancer	0.000203	0.00676	CbGpPWpGaD
Pethidine—GRIN1—CREB phosphorylation through the activation of Ras—HRAS—skin cancer	0.000192	0.00639	CbGpPWpGaD
Pethidine—GRIN2B—CREB phosphorylation through the activation of Ras—HRAS—skin cancer	0.000187	0.00623	CbGpPWpGaD
Pethidine—SLC6A2—SLC-mediated transmembrane transport—SLC12A2—skin cancer	0.000187	0.00622	CbGpPWpGaD
Pethidine—Hypersensitivity—Docetaxel—skin cancer	0.000184	0.00187	CcSEcCtD
Pethidine—OPRM1—Peptide ligand-binding receptors—MC1R—skin cancer	0.000183	0.00609	CbGpPWpGaD
Pethidine—GRIN2A—Post NMDA receptor activation events—HRAS—skin cancer	0.000181	0.00603	CbGpPWpGaD
Pethidine—Asthenia—Docetaxel—skin cancer	0.000179	0.00182	CcSEcCtD
Pethidine—GRIN2C—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—skin cancer	0.000178	0.00592	CbGpPWpGaD
Pethidine—Pruritus—Docetaxel—skin cancer	0.000177	0.0018	CcSEcCtD
Pethidine—GRIN1—Developmental Biology—SCN10A—skin cancer	0.000173	0.00577	CbGpPWpGaD
Pethidine—OPRK1—GPCRs, Class A Rhodopsin-like—MC1R—skin cancer	0.000169	0.00564	CbGpPWpGaD
Pethidine—GRIN2B—Developmental Biology—SCN10A—skin cancer	0.000169	0.00562	CbGpPWpGaD
Pethidine—GRIN2A—Activation of NMDA receptor upon glutamate binding and postsynaptic events—HRAS—skin cancer	0.000167	0.00555	CbGpPWpGaD
Pethidine—SLC6A3—SLC-mediated transmembrane transport—SLC12A2—skin cancer	0.000165	0.00551	CbGpPWpGaD
Pethidine—GRIN2D—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—skin cancer	0.000165	0.0055	CbGpPWpGaD
Pethidine—Dizziness—Docetaxel—skin cancer	0.000165	0.00168	CcSEcCtD
Pethidine—Vomiting—Docetaxel—skin cancer	0.000159	0.00162	CcSEcCtD
Pethidine—GRIN1—Post NMDA receptor activation events—HRAS—skin cancer	0.000158	0.00526	CbGpPWpGaD
Pethidine—Rash—Docetaxel—skin cancer	0.000158	0.0016	CcSEcCtD
Pethidine—Dermatitis—Docetaxel—skin cancer	0.000157	0.0016	CcSEcCtD
Pethidine—Headache—Docetaxel—skin cancer	0.000157	0.00159	CcSEcCtD
Pethidine—GRIN2B—Post NMDA receptor activation events—HRAS—skin cancer	0.000154	0.00512	CbGpPWpGaD
Pethidine—GRIN1—Spinal Cord Injury—CDK4—skin cancer	0.000153	0.00511	CbGpPWpGaD
Pethidine—OPRK1—GPCR ligand binding—PTCH2—skin cancer	0.000153	0.00509	CbGpPWpGaD
Pethidine—Nausea—Docetaxel—skin cancer	0.000149	0.00151	CcSEcCtD
Pethidine—GRIN1—EPHB-mediated forward signaling—HRAS—skin cancer	0.000145	0.00484	CbGpPWpGaD
Pethidine—GRIN1—Activation of NMDA receptor upon glutamate binding and postsynaptic events—HRAS—skin cancer	0.000145	0.00484	CbGpPWpGaD
Pethidine—OPRK1—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	0.000145	0.00483	CbGpPWpGaD
Pethidine—OPRM1—GPCRs, Class A Rhodopsin-like—MC1R—skin cancer	0.000143	0.00476	CbGpPWpGaD
Pethidine—GRIN2B—EPHB-mediated forward signaling—HRAS—skin cancer	0.000142	0.00472	CbGpPWpGaD
Pethidine—GRIN2B—Activation of NMDA receptor upon glutamate binding and postsynaptic events—HRAS—skin cancer	0.000142	0.00472	CbGpPWpGaD
Pethidine—GRIN1—Axon guidance—RASA1—skin cancer	0.000139	0.00464	CbGpPWpGaD
Pethidine—GRIN2B—Axon guidance—RASA1—skin cancer	0.000136	0.00453	CbGpPWpGaD
Pethidine—GRIN2A—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—skin cancer	0.000136	0.00452	CbGpPWpGaD
Pethidine—GRIN2C—Alzheimers Disease—TP53—skin cancer	0.000135	0.0045	CbGpPWpGaD
Pethidine—GRIN2C—Transmission across Chemical Synapses—BRAF—skin cancer	0.000134	0.00445	CbGpPWpGaD
Pethidine—OPRM1—GPCR ligand binding—PTCH2—skin cancer	0.000129	0.0043	CbGpPWpGaD
Pethidine—GRIN2D—Alzheimers Disease—TP53—skin cancer	0.000126	0.00418	CbGpPWpGaD
Pethidine—GRIN2D—Transmission across Chemical Synapses—BRAF—skin cancer	0.000124	0.00414	CbGpPWpGaD
Pethidine—OPRM1—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	0.000123	0.00408	CbGpPWpGaD
Pethidine—GRIN1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—skin cancer	0.000118	0.00394	CbGpPWpGaD
Pethidine—GRIN2B—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—skin cancer	0.000115	0.00384	CbGpPWpGaD
Pethidine—OPRK1—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	0.000111	0.00371	CbGpPWpGaD
Pethidine—OPRK1—GPCR ligand binding—MC1R—skin cancer	0.00011	0.00368	CbGpPWpGaD
Pethidine—GRIN1—Spinal Cord Injury—PTGS2—skin cancer	0.00011	0.00365	CbGpPWpGaD
Pethidine—GRIN2A—Alzheimers Disease—TP53—skin cancer	0.000103	0.00343	CbGpPWpGaD
Pethidine—GRIN2C—Neuronal System—BRAF—skin cancer	0.000102	0.00341	CbGpPWpGaD
Pethidine—GRIN2A—Transmission across Chemical Synapses—BRAF—skin cancer	0.000102	0.0034	CbGpPWpGaD
Pethidine—GRIN1—Developmental Biology—RASA1—skin cancer	9.95e-05	0.00331	CbGpPWpGaD
Pethidine—GRIN2B—Developmental Biology—RASA1—skin cancer	9.7e-05	0.00323	CbGpPWpGaD
Pethidine—OPRK1—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	9.54e-05	0.00318	CbGpPWpGaD
Pethidine—GRIN2D—Neuronal System—BRAF—skin cancer	9.52e-05	0.00317	CbGpPWpGaD
Pethidine—SLC6A2—Transmembrane transport of small molecules—SLC12A2—skin cancer	9.49e-05	0.00316	CbGpPWpGaD
Pethidine—OPRK1—Signaling Pathways—RHOU—skin cancer	9.49e-05	0.00316	CbGpPWpGaD
Pethidine—OPRM1—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	9.41e-05	0.00313	CbGpPWpGaD
Pethidine—ALB—SLC-mediated transmembrane transport—SLC12A2—skin cancer	9.39e-05	0.00313	CbGpPWpGaD
Pethidine—OPRM1—GPCR ligand binding—MC1R—skin cancer	9.34e-05	0.00311	CbGpPWpGaD
Pethidine—GRIN1—Alzheimers Disease—TP53—skin cancer	9e-05	0.003	CbGpPWpGaD
Pethidine—GRIN1—Transmission across Chemical Synapses—BRAF—skin cancer	8.9e-05	0.00296	CbGpPWpGaD
Pethidine—GRIN2B—Alzheimers Disease—TP53—skin cancer	8.77e-05	0.00292	CbGpPWpGaD
Pethidine—GRIN2B—Transmission across Chemical Synapses—BRAF—skin cancer	8.68e-05	0.00289	CbGpPWpGaD
Pethidine—SLC6A3—Transmembrane transport of small molecules—SLC12A2—skin cancer	8.41e-05	0.0028	CbGpPWpGaD
Pethidine—GRIN2C—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—skin cancer	8.18e-05	0.00272	CbGpPWpGaD
Pethidine—OPRM1—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	8.06e-05	0.00268	CbGpPWpGaD
Pethidine—OPRM1—Signaling Pathways—RHOU—skin cancer	8.02e-05	0.00267	CbGpPWpGaD
Pethidine—OPRK1—GPCR ligand binding—SHH—skin cancer	7.87e-05	0.00262	CbGpPWpGaD
Pethidine—OPRK1—Signaling by GPCR—PTCH2—skin cancer	7.84e-05	0.00261	CbGpPWpGaD
Pethidine—GRIN2A—Neuronal System—BRAF—skin cancer	7.82e-05	0.0026	CbGpPWpGaD
Pethidine—GRIN2D—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—skin cancer	7.6e-05	0.00253	CbGpPWpGaD
Pethidine—SLC6A4—Circadian rythm related genes—CDK4—skin cancer	7.52e-05	0.0025	CbGpPWpGaD
Pethidine—GRIN1—EPH-Ephrin signaling—HRAS—skin cancer	7.49e-05	0.00249	CbGpPWpGaD
Pethidine—OPRK1—GPCR ligand binding—SMO—skin cancer	7.46e-05	0.00248	CbGpPWpGaD
Pethidine—OPRK1—GPCR ligand binding—PTCH1—skin cancer	7.46e-05	0.00248	CbGpPWpGaD
Pethidine—GRIN2B—EPH-Ephrin signaling—HRAS—skin cancer	7.3e-05	0.00243	CbGpPWpGaD
Pethidine—OPRK1—GPCR ligand binding—PTGER4—skin cancer	7.26e-05	0.00242	CbGpPWpGaD
Pethidine—GRIN1—Neuronal System—BRAF—skin cancer	6.82e-05	0.00227	CbGpPWpGaD
Pethidine—OPRM1—GPCR ligand binding—SHH—skin cancer	6.65e-05	0.00221	CbGpPWpGaD
Pethidine—GRIN2B—Neuronal System—BRAF—skin cancer	6.65e-05	0.00221	CbGpPWpGaD
Pethidine—OPRM1—Signaling by GPCR—PTCH2—skin cancer	6.63e-05	0.00221	CbGpPWpGaD
Pethidine—GRIN1—Spinal Cord Injury—TP53—skin cancer	6.53e-05	0.00217	CbGpPWpGaD
Pethidine—CYP2C19—Arachidonic acid metabolism—PTGS2—skin cancer	6.34e-05	0.00211	CbGpPWpGaD
Pethidine—OPRM1—GPCR ligand binding—SMO—skin cancer	6.31e-05	0.0021	CbGpPWpGaD
Pethidine—OPRM1—GPCR ligand binding—PTCH1—skin cancer	6.31e-05	0.0021	CbGpPWpGaD
Pethidine—GRIN2A—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—skin cancer	6.24e-05	0.00208	CbGpPWpGaD
Pethidine—OPRK1—GPCR downstream signaling—MC1R—skin cancer	6.24e-05	0.00208	CbGpPWpGaD
Pethidine—GRIN2C—Transmission across Chemical Synapses—HRAS—skin cancer	6.15e-05	0.00205	CbGpPWpGaD
Pethidine—OPRM1—GPCR ligand binding—PTGER4—skin cancer	6.14e-05	0.00204	CbGpPWpGaD
Pethidine—GRIN1—Spinal Cord Injury—IL6—skin cancer	5.98e-05	0.00199	CbGpPWpGaD
Pethidine—GRIN2D—Transmission across Chemical Synapses—HRAS—skin cancer	5.72e-05	0.0019	CbGpPWpGaD
Pethidine—OPRK1—Signaling by GPCR—MC1R—skin cancer	5.67e-05	0.00189	CbGpPWpGaD
Pethidine—GRIN1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—skin cancer	5.45e-05	0.00181	CbGpPWpGaD
Pethidine—GRIN1—BDNF signaling pathway—HRAS—skin cancer	5.32e-05	0.00177	CbGpPWpGaD
Pethidine—GRIN2B—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—skin cancer	5.31e-05	0.00177	CbGpPWpGaD
Pethidine—ALB—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	5.29e-05	0.00176	CbGpPWpGaD
Pethidine—OPRM1—GPCR downstream signaling—MC1R—skin cancer	5.28e-05	0.00176	CbGpPWpGaD
Pethidine—GRIN2B—BDNF signaling pathway—HRAS—skin cancer	5.19e-05	0.00173	CbGpPWpGaD
Pethidine—SLC6A3—Transmission across Chemical Synapses—BRAF—skin cancer	5.09e-05	0.00169	CbGpPWpGaD
Pethidine—GRIN1—Developmental Biology—CDK4—skin cancer	4.88e-05	0.00163	CbGpPWpGaD
Pethidine—OPRM1—Signaling by GPCR—MC1R—skin cancer	4.79e-05	0.0016	CbGpPWpGaD
Pethidine—GRIN1—SIDS Susceptibility Pathways—IL6—skin cancer	4.78e-05	0.00159	CbGpPWpGaD
Pethidine—ALB—Transmembrane transport of small molecules—SLC12A2—skin cancer	4.77e-05	0.00159	CbGpPWpGaD
Pethidine—GRIN2B—Developmental Biology—CDK4—skin cancer	4.76e-05	0.00158	CbGpPWpGaD
Pethidine—CYP2C19—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	4.75e-05	0.00158	CbGpPWpGaD
Pethidine—GRIN2C—Neuronal System—HRAS—skin cancer	4.71e-05	0.00157	CbGpPWpGaD
Pethidine—OPRM1—TCR Signaling Pathway—HRAS—skin cancer	4.69e-05	0.00156	CbGpPWpGaD
Pethidine—GRIN2A—Transmission across Chemical Synapses—HRAS—skin cancer	4.69e-05	0.00156	CbGpPWpGaD
Pethidine—OPRK1—Signaling Pathways—PTCH2—skin cancer	4.63e-05	0.00154	CbGpPWpGaD
Pethidine—ALB—Selenium Micronutrient Network—PTGS2—skin cancer	4.5e-05	0.0015	CbGpPWpGaD
Pethidine—OPRM1—TCR Signaling Pathway—IL6—skin cancer	4.49e-05	0.0015	CbGpPWpGaD
Pethidine—GRIN2D—Neuronal System—HRAS—skin cancer	4.38e-05	0.00146	CbGpPWpGaD
Pethidine—OPRK1—GPCR downstream signaling—PTGER4—skin cancer	4.11e-05	0.00137	CbGpPWpGaD
Pethidine—GRIN1—Transmission across Chemical Synapses—HRAS—skin cancer	4.09e-05	0.00136	CbGpPWpGaD
Pethidine—OPRK1—Signaling by GPCR—SHH—skin cancer	4.04e-05	0.00134	CbGpPWpGaD
Pethidine—GRIN2B—Transmission across Chemical Synapses—HRAS—skin cancer	3.99e-05	0.00133	CbGpPWpGaD
Pethidine—OPRM1—Signaling Pathways—PTCH2—skin cancer	3.92e-05	0.0013	CbGpPWpGaD
Pethidine—SLC6A3—Neuronal System—BRAF—skin cancer	3.9e-05	0.0013	CbGpPWpGaD
Pethidine—OPRK1—Signaling by GPCR—SMO—skin cancer	3.83e-05	0.00127	CbGpPWpGaD
Pethidine—OPRK1—Signaling by GPCR—PTCH1—skin cancer	3.83e-05	0.00127	CbGpPWpGaD
Pethidine—GRIN1—Axon guidance—NRAS—skin cancer	3.8e-05	0.00127	CbGpPWpGaD
Pethidine—ALB—Vitamin B12 Metabolism—IL6—skin cancer	3.79e-05	0.00126	CbGpPWpGaD
Pethidine—OPRK1—Signaling by GPCR—PTGER4—skin cancer	3.73e-05	0.00124	CbGpPWpGaD
Pethidine—GRIN2B—Axon guidance—NRAS—skin cancer	3.71e-05	0.00123	CbGpPWpGaD
Pethidine—GRIN2A—Neuronal System—HRAS—skin cancer	3.6e-05	0.0012	CbGpPWpGaD
Pethidine—SLC6A4—SIDS Susceptibility Pathways—IL6—skin cancer	3.58e-05	0.00119	CbGpPWpGaD
Pethidine—OPRK1—Signaling Pathways—GLI2—skin cancer	3.51e-05	0.00117	CbGpPWpGaD
Pethidine—OPRM1—GPCR downstream signaling—PTGER4—skin cancer	3.47e-05	0.00116	CbGpPWpGaD
Pethidine—OPRM1—Signaling by GPCR—SHH—skin cancer	3.41e-05	0.00114	CbGpPWpGaD
Pethidine—ALB—Folate Metabolism—TP53—skin cancer	3.37e-05	0.00112	CbGpPWpGaD
Pethidine—OPRK1—Signaling Pathways—MC1R—skin cancer	3.35e-05	0.00111	CbGpPWpGaD
Pethidine—OPRK1—Signaling Pathways—GLI1—skin cancer	3.3e-05	0.0011	CbGpPWpGaD
Pethidine—GRIN1—Axon guidance—KRAS—skin cancer	3.27e-05	0.00109	CbGpPWpGaD
Pethidine—OPRM1—Signaling by GPCR—PTCH1—skin cancer	3.24e-05	0.00108	CbGpPWpGaD
Pethidine—OPRM1—Signaling by GPCR—SMO—skin cancer	3.24e-05	0.00108	CbGpPWpGaD
Pethidine—SLC6A4—Circadian rythm related genes—TP53—skin cancer	3.2e-05	0.00106	CbGpPWpGaD
Pethidine—GRIN2B—Axon guidance—KRAS—skin cancer	3.19e-05	0.00106	CbGpPWpGaD
Pethidine—OPRM1—Signaling by GPCR—PTGER4—skin cancer	3.15e-05	0.00105	CbGpPWpGaD
Pethidine—GRIN1—Neuronal System—HRAS—skin cancer	3.14e-05	0.00104	CbGpPWpGaD
Pethidine—OPRK1—Signaling Pathways—SUFU—skin cancer	3.13e-05	0.00104	CbGpPWpGaD
Pethidine—ALB—Folate Metabolism—IL6—skin cancer	3.08e-05	0.00103	CbGpPWpGaD
Pethidine—GRIN2B—Neuronal System—HRAS—skin cancer	3.06e-05	0.00102	CbGpPWpGaD
Pethidine—OPRM1—Signaling Pathways—GLI2—skin cancer	2.97e-05	0.000988	CbGpPWpGaD
Pethidine—SLC6A4—Circadian rythm related genes—IL6—skin cancer	2.93e-05	0.000974	CbGpPWpGaD
Pethidine—OPRM1—Signaling Pathways—MC1R—skin cancer	2.83e-05	0.000942	CbGpPWpGaD
Pethidine—CYP2B6—Metabolism—PLIN2—skin cancer	2.8e-05	0.000932	CbGpPWpGaD
Pethidine—OPRM1—Signaling Pathways—GLI1—skin cancer	2.79e-05	0.000929	CbGpPWpGaD
Pethidine—GRIN1—Axon guidance—HRAS—skin cancer	2.78e-05	0.000926	CbGpPWpGaD
Pethidine—GRIN1—Developmental Biology—NRAS—skin cancer	2.71e-05	0.000904	CbGpPWpGaD
Pethidine—GRIN2B—Axon guidance—HRAS—skin cancer	2.71e-05	0.000903	CbGpPWpGaD
Pethidine—GRIN1—Axon guidance—IL6—skin cancer	2.66e-05	0.000887	CbGpPWpGaD
Pethidine—GRIN2B—Developmental Biology—NRAS—skin cancer	2.65e-05	0.000881	CbGpPWpGaD
Pethidine—OPRM1—Signaling Pathways—SUFU—skin cancer	2.64e-05	0.00088	CbGpPWpGaD
Pethidine—GRIN2B—Axon guidance—IL6—skin cancer	2.6e-05	0.000864	CbGpPWpGaD
Pethidine—ALB—Selenium Micronutrient Network—IL6—skin cancer	2.45e-05	0.000815	CbGpPWpGaD
Pethidine—OPRK1—Signaling Pathways—SHH—skin cancer	2.39e-05	0.000794	CbGpPWpGaD
Pethidine—OPRK1—Signaling Pathways—RASA1—skin cancer	2.37e-05	0.000789	CbGpPWpGaD
Pethidine—ALB—Metabolism—PLIN2—skin cancer	2.36e-05	0.000785	CbGpPWpGaD
Pethidine—SLC6A3—Transmission across Chemical Synapses—HRAS—skin cancer	2.34e-05	0.000779	CbGpPWpGaD
Pethidine—GRIN1—Developmental Biology—KRAS—skin cancer	2.34e-05	0.000778	CbGpPWpGaD
Pethidine—GRIN2B—Developmental Biology—KRAS—skin cancer	2.28e-05	0.000758	CbGpPWpGaD
Pethidine—OPRK1—Signaling Pathways—PTCH1—skin cancer	2.26e-05	0.000753	CbGpPWpGaD
Pethidine—OPRK1—Signaling Pathways—SMO—skin cancer	2.26e-05	0.000753	CbGpPWpGaD
Pethidine—CYP2B6—Metabolism—CSPG4—skin cancer	2.26e-05	0.000751	CbGpPWpGaD
Pethidine—OPRK1—Signaling Pathways—PTGER4—skin cancer	2.2e-05	0.000733	CbGpPWpGaD
Pethidine—CYP2C19—Metabolism—PLIN2—skin cancer	2.12e-05	0.000704	CbGpPWpGaD
Pethidine—OPRM1—Signaling Pathways—SHH—skin cancer	2.02e-05	0.000671	CbGpPWpGaD
Pethidine—OPRM1—Signaling Pathways—RASA1—skin cancer	2e-05	0.000667	CbGpPWpGaD
Pethidine—GRIN1—Developmental Biology—HRAS—skin cancer	1.99e-05	0.000661	CbGpPWpGaD
Pethidine—CYP2D6—Metabolism—PLIN2—skin cancer	1.95e-05	0.000648	CbGpPWpGaD
Pethidine—OPRK1—Signaling Pathways—FOXO4—skin cancer	1.95e-05	0.000648	CbGpPWpGaD
Pethidine—GRIN2B—Developmental Biology—HRAS—skin cancer	1.94e-05	0.000644	CbGpPWpGaD
Pethidine—OPRM1—Signaling Pathways—PTCH1—skin cancer	1.91e-05	0.000637	CbGpPWpGaD
Pethidine—OPRM1—Signaling Pathways—SMO—skin cancer	1.91e-05	0.000637	CbGpPWpGaD
Pethidine—GRIN1—Developmental Biology—IL6—skin cancer	1.9e-05	0.000633	CbGpPWpGaD
Pethidine—ALB—Metabolism—CSPG4—skin cancer	1.9e-05	0.000632	CbGpPWpGaD
Pethidine—OPRM1—Signaling Pathways—PTGER4—skin cancer	1.86e-05	0.00062	CbGpPWpGaD
Pethidine—GRIN2B—Developmental Biology—IL6—skin cancer	1.85e-05	0.000617	CbGpPWpGaD
Pethidine—SLC6A3—Neuronal System—HRAS—skin cancer	1.79e-05	0.000597	CbGpPWpGaD
Pethidine—CYP2C19—Metabolism—CSPG4—skin cancer	1.71e-05	0.000568	CbGpPWpGaD
Pethidine—OPRM1—Signaling Pathways—FOXO4—skin cancer	1.64e-05	0.000547	CbGpPWpGaD
Pethidine—CYP2D6—Metabolism—CSPG4—skin cancer	1.57e-05	0.000522	CbGpPWpGaD
Pethidine—CYP2B6—Metabolism—ENO2—skin cancer	1.53e-05	0.000511	CbGpPWpGaD
Pethidine—OPRK1—Signaling Pathways—TERT—skin cancer	1.3e-05	0.000433	CbGpPWpGaD
Pethidine—ALB—Metabolism—ENO2—skin cancer	1.29e-05	0.00043	CbGpPWpGaD
Pethidine—CYP3A4—Metabolism—PLIN2—skin cancer	1.27e-05	0.000424	CbGpPWpGaD
Pethidine—CYP2C19—Metabolism—ENO2—skin cancer	1.16e-05	0.000386	CbGpPWpGaD
Pethidine—OPRM1—Signaling Pathways—TERT—skin cancer	1.1e-05	0.000366	CbGpPWpGaD
Pethidine—OPRK1—Signaling by GPCR—NRAS—skin cancer	1.09e-05	0.000364	CbGpPWpGaD
Pethidine—CYP2D6—Metabolism—ENO2—skin cancer	1.07e-05	0.000355	CbGpPWpGaD
Pethidine—OPRK1—Signaling Pathways—BRAF—skin cancer	1.03e-05	0.000343	CbGpPWpGaD
Pethidine—CYP3A4—Metabolism—CSPG4—skin cancer	1.03e-05	0.000341	CbGpPWpGaD
Pethidine—ALB—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.01e-05	0.000336	CbGpPWpGaD
Pethidine—OPRK1—Signaling by GPCR—KRAS—skin cancer	9.42e-06	0.000314	CbGpPWpGaD
Pethidine—OPRM1—Signaling by GPCR—NRAS—skin cancer	9.25e-06	0.000308	CbGpPWpGaD
Pethidine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	9.07e-06	0.000302	CbGpPWpGaD
Pethidine—CYP2B6—Metabolism—ERCC2—skin cancer	8.91e-06	0.000297	CbGpPWpGaD
Pethidine—OPRM1—Signaling Pathways—BRAF—skin cancer	8.7e-06	0.00029	CbGpPWpGaD
Pethidine—ALB—Hemostasis—NRAS—skin cancer	8.63e-06	0.000287	CbGpPWpGaD
Pethidine—OPRK1—Signaling by GPCR—HRAS—skin cancer	8.01e-06	0.000267	CbGpPWpGaD
Pethidine—OPRM1—Signaling by GPCR—KRAS—skin cancer	7.96e-06	0.000265	CbGpPWpGaD
Pethidine—OPRK1—Signaling by GPCR—IL6—skin cancer	7.67e-06	0.000255	CbGpPWpGaD
Pethidine—ALB—Metabolism—ERCC2—skin cancer	7.5e-06	0.00025	CbGpPWpGaD
Pethidine—ALB—Hemostasis—KRAS—skin cancer	7.43e-06	0.000247	CbGpPWpGaD
Pethidine—CYP3A4—Metabolism—ENO2—skin cancer	6.97e-06	0.000232	CbGpPWpGaD
Pethidine—OPRM1—Signaling by GPCR—HRAS—skin cancer	6.77e-06	0.000225	CbGpPWpGaD
Pethidine—CYP2C19—Metabolism—ERCC2—skin cancer	6.73e-06	0.000224	CbGpPWpGaD
Pethidine—ALB—Hemostasis—TP53—skin cancer	6.6e-06	0.00022	CbGpPWpGaD
Pethidine—OPRM1—Signaling by GPCR—IL6—skin cancer	6.48e-06	0.000216	CbGpPWpGaD
Pethidine—OPRK1—Signaling Pathways—NRAS—skin cancer	6.47e-06	0.000215	CbGpPWpGaD
Pethidine—ALB—Hemostasis—HRAS—skin cancer	6.31e-06	0.00021	CbGpPWpGaD
Pethidine—CYP2D6—Metabolism—ERCC2—skin cancer	6.19e-06	0.000206	CbGpPWpGaD
Pethidine—OPRK1—Signaling Pathways—KRAS—skin cancer	5.57e-06	0.000185	CbGpPWpGaD
Pethidine—OPRM1—Signaling Pathways—NRAS—skin cancer	5.47e-06	0.000182	CbGpPWpGaD
Pethidine—CYP2B6—Metabolism—PTGS2—skin cancer	5.34e-06	0.000178	CbGpPWpGaD
Pethidine—OPRK1—Signaling Pathways—TP53—skin cancer	4.95e-06	0.000165	CbGpPWpGaD
Pethidine—OPRK1—Signaling Pathways—HRAS—skin cancer	4.73e-06	0.000158	CbGpPWpGaD
Pethidine—OPRM1—Signaling Pathways—KRAS—skin cancer	4.7e-06	0.000157	CbGpPWpGaD
Pethidine—OPRK1—Signaling Pathways—IL6—skin cancer	4.53e-06	0.000151	CbGpPWpGaD
Pethidine—ALB—Metabolism—PTGS2—skin cancer	4.5e-06	0.00015	CbGpPWpGaD
Pethidine—OPRM1—Signaling Pathways—TP53—skin cancer	4.18e-06	0.000139	CbGpPWpGaD
Pethidine—CYP3A4—Metabolism—ERCC2—skin cancer	4.05e-06	0.000135	CbGpPWpGaD
Pethidine—CYP2C19—Metabolism—PTGS2—skin cancer	4.04e-06	0.000134	CbGpPWpGaD
Pethidine—OPRM1—Signaling Pathways—HRAS—skin cancer	4e-06	0.000133	CbGpPWpGaD
Pethidine—OPRM1—Signaling Pathways—IL6—skin cancer	3.83e-06	0.000127	CbGpPWpGaD
Pethidine—CYP2D6—Metabolism—PTGS2—skin cancer	3.71e-06	0.000124	CbGpPWpGaD
Pethidine—CYP3A4—Metabolism—PTGS2—skin cancer	2.43e-06	8.08e-05	CbGpPWpGaD
